Memorial Sloan-Kettering is the first and only hospital in New York, New Jersey, and Connecticut to offer a new, more patient-friendly approach for doctors to precisely pinpoint and remove small breast cancers.

In a large-scale genome-sequencing study, researchers have discovered mutations in neuroblastoma tumors that could aid the development of diagnostic tests and therapies.

Findings from a multidisciplinary research team led by Memorial Sloan-Kettering medical oncologist and immunologist Jedd Wolchok could help shed light on the immune system’s role in fighting cancer.

Memorial Sloan-Kettering investigators have developed a personalized tool to help women and their doctors predict overall survival at five years after a diagnosis of uterine leiomyosarcoma.

For the first time, a new study has shown that removing polyps by colonoscopy not only prevents colorectal cancer from developing, but also prevents deaths from the disease.

Two Memorial Sloan-Kettering studies provide new clues about genetic mutations that affect cell behavior and play a role in several types of cancer.

Soon after Halina Frydman’s husband noticed changes in his wife's personality, Halina was diagnosed with primary central nervous system lymphoma. She came to Memorial Sloan-Kettering to receive treatment through a clinical trial.